Albiglutide Drugbank ID : DB09043

Description : Indication : Pharmacodynamics : Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA. Indication : As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Pharmacodynamics : It lowers fasting glucose and reduces postprandial glucose excursions in patients with type 2 diabetes mellitus. The majority of the observed reduction in fasting plasma glucose occurs after a single dose, consistent with the pharmacokinetic profile of albiglutide

Mechanism of action : Albiglutide is an agonist of the GLP-1 (glucagon-like peptide 1) receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying.

Targets : Affected organisms : Categories : Glucagon-like peptide 1 receptor Affected organisms : Humans and other mammals Categories : Alimentary Tract and Metabolism Blood Glucose Lowering Agents Blood Glucose Lowering Drugs, Excl. Insulins Chemical Actions and Uses Drugs Used in Diabetes GLP-1 Agonists Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Incretins Pharmacologic Actions Physiological Effects of Drugs Recombinant Proteins

Sequence : HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL

Brands : Eperzan Company : Glaxosmithkline Inc Description : Eperzan or albiglutide is a recombinant fusion protein consisting of two copies of a 30-amino acid sequence of modified human glucagon-like peptide 1 genetically fused series to human albumin. It is produced in Saccharomyces cerevisiae cells by recombinant DNA technology. Used for/Prescribed for : Eperzan is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control either as monotherapy or add-on combination therapy. Formulation : As 30 mg powder and solvent for solution for injection. Each pen delivers 30 mg albiglutide per 0.5 ml dose following reconstitution. Form : lyophilised white to yellow powder Route of administration : subcutaneous

Risk of acute pancreatitis; Hypoglycaemia; Diarrhoea; Nausea; Rash, redness or itching of the skin where eperzan is injected; Pneumonia; Irregular heartbeat; Constipation; Indigestion; Heartburn; Albiglutide delays gastric emptying, and has the potential to impact the absorption of concomitantly administered oral medicinal products. It shows major interactions with acarbose, simvastatin, digoxin, warfarin and oral contraceptives.

References : http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002735/WC500165117.pdf http://www.drugbank.ca/drugs/DB09043